Advertisement
Advertisement
TOPIC
 / company

BeOne

BeOne
The latest news and top stories on BeOne Medicines. Hong Kong-listed BeOne Medicines, formerly BeiGene, specialises in developing and selling innovative oncology products. Headquartered in Beijing China with global operations, they primarily serve cancer patients worldwide, addressing unmet medical needs. Notable for its rapid growth and pioneering advancements in immuno-oncology, the company's key products include the blood cancer drug zanubrutinib (Brukinsa) and the oncology drug tislelizumab (Tevimbra). BeOne Medicines anticipates significant net profit, reflecting its focus on transforming cancer treatment through cutting-edge research and global expansion.
Hong Kong stock market

Hang Seng Index adds major Chinese chipmaker as tech pivot continues

Hong Kong’s bellwether stock index has added two new companies including contract chipmaker Hua Hong Grace Semiconductor.

China’s tax crackdown: A-share and Hong Kong-listed firms hit hard

China’s biotech boom drives surge in home-grown innovative drug approvals

Domestic firms dominate China’s drug approvals amid jump in spending and out-licensing deals as regulator speeds path to market.

Hang Seng Index review to boost market capitalisation by 4.5%: analysts

Tencent, BeOne Medicines, Baidu and NetEase may lure fund inflows between US$200 million and US$1 billion, due to index weighting changes.

videocam
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement